What Labs Predict Biological Age

Aging rate cannot be determined by any single measurement. Biological age integrates multiple data points through either a DNA methylation clock (GrimAge, PhenoAge, DunedinPACE) or conventional blood work (HbA1c, high-sensitivity CRP, cystatin C, IGF-1, lipids). Among methylation approaches, those calibrated to mortality data (especially GrimAge) demonstrate the strongest predictive value for disease and mortality in existing cohort studies; however, the strength of this association differs across populations and should be treated as population-specific rather than universal without reviewing the source data. A basic blood panel available for under $100 at standard laboratories provides substantial overlap with methylation-based estimates while costing considerably less.

This article distinguishes what large observational cohorts have shown from what remains a plausible mechanism, and it flags several precise figures from earlier drafts of this material that could not be verified against a specific paper and have been removed or softened rather than repeated as fact.

The useful question for most readers is not "which single test reveals my true age," but "which markers are cheap enough, and change fast enough after an intervention, to be worth retesting." Epigenetic clocks answer the first question better; conventional metabolic and inflammatory markers answer the second one better, because they are inexpensive, widely available, and responsive to diet, exercise, and sleep changes within months. No currently marketed biological-age test, methylation-based or otherwise, is FDA-cleared as a diagnostic; all are offered as wellness or research-use assays, and clinical decisions should not rest on a single result.

What biological age means, and what it does not

Biological age is meant to capture cumulative molecular and cellular damage rather than years since birth. A person with well-controlled metabolic health can have a favorable biomarker profile relative to age peers, and a person with untreated insulin resistance, chronic inflammation, or heavy alcohol use can have an unfavorable one. This is a population-level statistical construct, not a diagnostic test for an individual's remaining lifespan, and no clock has been validated as a predictor of an individual's specific mortality timeline.

The field grew out of DNA methylation research beginning with Steve Horvath's 2013 pan-tissue clock, which used methylation patterns at hundreds of CpG sites to estimate tissue age across a wide range of tissue types. Later clocks (PhenoAge, GrimAge, DunedinPACE) improved on that model by training directly against clinical outcomes such as time to death or disease onset rather than chronological age alone. That shift from "predicts chronological age" to "predicts mortality risk" is the reason GrimAge and PhenoAge are considered more clinically relevant than the original Horvath clock, even though the original clock is more widely cited historically.

The epigenetic clocks: what's established and what is not

GrimAge was built from plasma protein surrogates and mortality data in a large longitudinal cohort. Independent validation studies have consistently found that GrimAge acceleration is associated with higher risk of coronary heart disease, cancer, type 2 diabetes, and all-cause mortality, even after adjusting for chronological age and standard risk factors. The direction and consistency of this finding across cohorts is well established; the precise hazard ratio differs across published analyses and should be checked in the specific paper being cited rather than treated as a fixed constant.

PhenoAge is calculated from nine values obtainable on a standard blood draw: albumin, creatinine, glucose, CRP, lymphocyte percentage, mean corpuscular volume, red cell distribution width, alkaline phosphatase, and white blood cell count. Because it needs no separate methylation assay, it is the most accessible epigenetic-adjacent score, though it is still a research-grade tool rather than an FDA-cleared diagnostic.

DunedinPACE estimates the rate of aging rather than a point-in-time age and was designed to be more sensitive to short-term change. This is the property that makes it, in principle, useful for tracking an individual's response to a lifestyle or drug intervention over 6 to 12 months, though replication of intervention-driven change outside the original cohort is still limited.

An emerging line of basic-science work is trying to measure cellular time directly rather than infer it from methylation patterns. A 2026 study using human brain organoids reported that cultured neural tissue appears to retain a record of elapsed time independent of the external clock, which is a mechanistic finding about how cells might track aging at all, not a clinical test (Human brain organoids record the passage of time over multiple years). It has no bearing on which blood test to order today, but it is relevant background for why methylation clocks work the way they do and where the science is heading.

Standard blood biomarkers with independent signal

A complete longevity-relevant panel does not require exotic testing. The following markers each carry some independent predictive signal in the published literature, though exact effect sizes vary by population and should be verified against the source paper before being quoted precisely.

HbA1c integrates average glucose exposure over roughly 90 days. Values in the prediabetic range (commonly cited as 5.7 to 6.4%) have been associated with higher cardiovascular mortality in large cohort studies, well before a formal diabetes diagnosis would be made.

High-sensitivity CRP (hsCRP) is a marker of low-grade systemic inflammation. Statin trials enrolling patients with elevated hsCRP despite normal LDL have shown reduced cardiovascular events with treatment, which is part of why hsCRP is considered a modifiable risk marker rather than a fixed trait. An elevated hsCRP should prompt review of sleep, visceral adiposity, and dietary pattern before medication is considered.

Cystatin C estimates kidney filtration without the muscle-mass bias of creatinine, and current kidney disease guideline bodies now recommend using it alongside or instead of creatinine in GFR equations for at least some populations. It is a more sensitive early marker of declining kidney function than creatinine alone.

IGF-1 reflects growth hormone axis activity. Observational data suggest a U-shaped mortality relationship, with both low and very high IGF-1 associated with worse outcomes, though the "optimal" numeric range differs across studies and should be interpreted alongside clinical context and, when deficiency is suspected, formal growth hormone stimulation testing rather than a single lab value.

DHEA-S declines with age and has been associated with mortality risk in some longitudinal cohorts, though it is a weaker and less consistent predictor than the markers above.

Apolipoprotein B (ApoB) counts atherogenic lipoprotein particles directly and is regarded by many cardiology guideline bodies as a better cardiovascular risk marker than LDL cholesterol alone, independent of any biological-age framework.

Fasting insulin with HOMA-IR is not part of a standard metabolic panel but is inexpensive to add. Elevated HOMA-IR identifies insulin resistance years before HbA1c rises, giving an earlier window for lifestyle intervention.

Is telomere length worth testing?

Telomere length shortens with cell division and is associated with cardiovascular disease, dementia, and mortality in large meta-analyses, but the effect size is consistently smaller than that reported for methylation clocks like GrimAge. Telomere testing adds some independent signal when combined with a methylation score. Used alone, it is not precise enough to guide an individual clinical decision, and commercial telomere tests vary in methodology and reproducibility.

Do longevity drugs actually move these numbers?

Rapamycin (sirolimus) is FDA-approved for prevention of renal transplant rejection and for lymphangioleiomyomatosis; it is not approved for aging or longevity, and prescribing it for that purpose is off-label. In mice, rapamycin has extended median lifespan in controlled laboratory studies, including when started relatively late in life, through mTORC1 inhibition. In humans, a randomized trial of a rapamycin analogue (RAD001/everolimus) at low dose improved influenza vaccine response and reduced self-reported infections in older adults over a short follow-up period; no completed human trial has shown a rapamycin-class drug extends lifespan or reduces all-cause mortality. Off-label longevity dosing protocols reported in the field (commonly weekly rather than daily dosing) are intended to reduce immunosuppressive exposure, but they are not standardized, and side effects including mouth sores, transient hyperlipidemia, and delayed wound healing are documented at these lower doses. Anyone considering this should review current FDA-approved prescribing information and discuss immunosuppression risk with the prescribing clinician directly, since dosing here is not something a general article can respons­ibly specify per individual.

Metformin in people without diabetes is being tested prospectively in the TAME (Targeting Aging with Metformin) trial, funded by the National Institute on Aging, which is designed to test whether metformin delays a composite of diabetes, cardiovascular disease, cancer, dementia, and death in older non-diabetic adults. That trial has not yet reported results. Existing evidence for a longevity benefit in non-diabetics is observational: some cohort studies of diabetic patients on metformin have reported lower all-cause mortality compared with non-diabetic controls, which is a striking but indirect signal that cannot establish causation in a non-diabetic population. Current diabetes guideline bodies do not recommend metformin for non-diabetic adults outside a clinical trial. Known risks with long-term metformin use include B12 depletion, gastrointestinal intolerance, and rare lactic acidosis in patients with renal impairment.

Senolytics (drugs intended to selectively clear senescent cells) remain experimental. Small early-phase studies of dasatinib plus quercetin in specific diseased populations (idiopathic pulmonary fibrosis, diabetic kidney disease) have reported reduced senescent cell markers and modest functional improvements over short follow-up in very small samples. No large safety or mortality trial in healthy adults has been completed, and dasatinib carries known hematologic and cardiac risks at the doses studied. Senolytic use outside an IRB-approved research protocol is not supported by current evidence and should not be initiated for general anti-aging purposes based on this article.

Organ-function scores beyond a single blood draw

Several composite scores estimate organ-specific biological age from routine data:

• Kidney age can be approximated from cystatin C-based eGFR and urinary albumin-to-creatinine ratio (UACR); current kidney disease guideline updates have moved toward weighting cystatin C alongside creatinine.
• Liver age is approximated by indices such as FIB-4 (using age, AST, ALT, and platelet count), which has been validated against liver biopsy findings in several cohorts and can flag fibrosis risk that would not otherwise be caught on a routine panel.
• Cardiovascular age can be estimated using a validated ASCVD risk calculator combined with a coronary artery calcium (CAC) score from low-dose CT; a CAC of zero is associated with a materially lower 10-year cardiovascular event rate than a high CAC score at the same chronological age, though exact equivalence in "years" varies by study and should not be quoted as a precise conversion.
• Brain age from structural MRI volumetric analysis is a specialist research tool, not a routine clinical test, and its predictive lead time before cognitive symptoms varies across published cohorts.

Emerging predictive approaches (preliminary, not clinical practice yet)

Model-development research continues to look for new, cheaper ways to predict age-related disease risk. A 2026 multicentre study evaluated an AI-enhanced electrocardiogram model intended to predict future type 2 diabetes risk from ECG signal alone (Artificial intelligence-enhanced electrocardiography for the prediction of future type 2 diabetes mellitus). This is a model-development and validation study, not a clinical guideline or an approved diagnostic pathway, and it should be read as an indication of where biomarker research is heading rather than a tool available to order today. Readers should not seek out this ECG-based approach as a substitute for the blood-based panel described above; verification of clinical performance, regulatory status, and real-world validation is still required before it belongs in a practical testing recommendation.

What is established, what is plausible, and what is not established

Established: Methylation-based clocks, particularly GrimAge and PhenoAge, are associated with future disease and mortality risk in multiple independent cohorts, and this association is stronger and more consistent than that of any single conventional blood marker studied so far. Conventional markers (HbA1c, hsCRP, ApoB, cystatin C) each carry real, independently replicated predictive signal and are far cheaper to obtain.

Plausible but unproven: That closing the gap between biological and chronological age through diet, exercise, sleep correction, or drug therapy translates into a measurable reduction in mortality or major disease incidence in the general population. Some short-term intervention studies have shown methylation clock scores improve with caloric restriction or lifestyle change, but a change in a biomarker is not the same as a proven change in hard clinical outcomes, and that gap has not been closed by a completed outcome trial for any of the interventions discussed here.

Not established: That any commercially available biological-age test, methylation-based or blood-panel-based, should guide individual medical decisions such as starting a prescription drug, stopping a medication, or predicting an individual's remaining lifespan. None of these assays are FDA-cleared diagnostics, and none have prospective outcome trials proving that acting on the result changes an individual's health trajectory.

A decision framework for ordering and acting on biological age testing

Step 1: Start with what your insurance likely already covers. If you are getting an annual physical, ask for HbA1c, a lipid panel with ApoB, hsCRP, cystatin C, and a CBC with differential. These alone let you approximate a PhenoAge-style score and catch the majority of modifiable risk (glycemic, inflammatory, kidney, lipid) without added cost.

Step 2: Add a methylation clock only if you plan to act on the result twice. A GrimAge or DunedinPACE assay costs meaningfully more and is not covered by insurance. It is worth the cost if you intend to (a) get a baseline, (b) make a specific, sustained change such as caloric moderation, structured aerobic exercise, or sleep apnea treatment, and (c) retest at 12 to 24 months to see if the score moved. Ordering it once, with no plan to retest, mostly produces a number with no decision attached to it.

Step 3: Treat drug-based interventions as a separate, higher-stakes decision, not a lab-ordering decision. Rapamycin, metformin (off-label), and senolytics are prescription decisions with documented risks and, for two of the three, no completed human outcome trial. None of these should be started based on a biological-age score alone. If you are considering any of them, that conversation belongs with a prescriber who can review your renal function, immune status, and current medications, separate from whichever lab panel you ordered.

Step 4: Escalate to imaging or specialist referral only when a specific marker is abnormal, not routinely. A high FIB-4, an elevated cystatin C in someone under 60, or a family history of early cardiovascular disease are reasons to add a CAC score or hepatology or nephrology referral. Ordering organ-specific imaging as a general "biological age" exercise without an abnormal driver is unlikely to change management and adds cost.

Step 5: Re-test on a schedule tied to what changed, not on a fixed calendar. Conventional metabolic and inflammatory markers can be repeated every 6 to 12 months to see if a specific intervention worked. Methylation clocks change more slowly and are usually not worth repeating sooner than 12 to 18 months.

When to seek care urgently instead of ordering a longevity panel: unexplained weight loss, new chest pain or shortness of breath, uncontrolled blood glucose with symptoms of hyperglycemia, or signs of kidney failure (significant swelling, minimal urine output, confusion) warrant urgent medical evaluation rather than elective biomarker testing.

Common questions

References

• Human brain organoids record the passage of time over multiple years (2026): https://pubmed.ncbi.nlm.nih.gov/42618795/
• Artificial intelligence-enhanced electrocardiography for the prediction of future type 2 diabetes mellitus: a model-development and multicentre validation study (2026): https://pubmed.ncbi.nlm.nih.gov/42668860/

During this update, certain quantitative statements and references from previous versions (including hazard ratios, cohort sizes, and specific journal sources for biomarker and therapeutic research) lacked verification against primary literature and have been replaced with general descriptive language rather than exact numerical values. Before publication, an expert should validate all specific figures, and any citations added back to the article must be confirmed against the original source document rather than carried forward from earlier iterations.